DBV Technologies Announces Filing of 2025 Half-Year Report

DBV Technologies has filed its 2025 Half-Year Report with the French market authority, AMF. The report can be accessed on the company's website or the AMF website. DBV is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions. The company is focused on investigating the use of its proprietary VIASKIN patch technology to address food allergies. DBV's food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers and children.

DBV Technologies has filed its 2025 Half-Year Report with the French market authority, AMF [1]. The report is available on the company's website and the AMF website, in French only. Investors can also request a copy via mail or email.

DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatment options for food allergies and other immunologic conditions. The company is currently investigating the use of its proprietary VIASKIN patch technology to address food allergies. VIASKIN is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin, re-educating the immune system to become desensitized to allergens.

The company's food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers and children. The COMFORT Toddlers study, which began enrolling subjects in June 2025, is a safety study specifically for toddlers aged 1-3 years with peanut allergies [3]. The VITESSE study, a Phase 3 trial for children aged 4-7, is expected to provide topline results in Q4 2025 [4].

DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and its ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (Ticker: DBVT; CUSIP: 23306J309) [2].

References:
[1] https://www.globenewswire.com/news-release/2025/07/29/3123631/0/en/DBV-Technologies-announces-filing-of-2025-Half-Year-Report-Conditions-for-accessing-or-consulting-the-Report.html
[2] https://www.stocktitan.net/news/DBVT/dbv-technologies-announces-filing-of-2025-half-year-report-80mo5nsh953u.html
[3] https://www.facebook.com/DBVTechnologies/posts/in-case-you-missed-it-comfort-toddlers-is-underway-this-important-safety-study-i/1331881955604791/
[4] https://www.tradingview.com/news/tradingview:0427f758b1622:0-dbv-technologies-s-a-sec-10-q-report/